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Introduction
Innate immune cells have a large array of defense mechanisms to 
handle bacterial infection. These are triggered upon recognition 
of pathogen-associated molecular patterns (PAMPs) by pattern 
recognition receptors (PRR), i.e., innate receptors (1, 2), including 
the Nacht, LRR and PYD domains-containing protein 3/NOD-
like receptor family, pyrin domain-containing 3 (NALP3/NLRP3) 
inflammasome (3–8). Recently defined danger-associated molec-
ular patterns (DAMPs) have also been associated with additional 
signals leading to activation of the NALP3 inflammasome and 
IL-1β secretion (3, 9, 10), allowing for rapid recruitment and acti-
vation of phagocytes (3, 11–13). DAMPs include intracellular host 
proteins, such as heat shock proteins (14), high-mobility group box 
1 (HMGB1) (15), and hyaluron fragments (16) as well as nonprotein 
molecules including ATP (7), uric acid (17), and DNA (18).
IL-1β secretion in response to PRR engagement requires cas-
pase-1 activation, which cleaves pro–IL-1β into its active mature 
secreted form (4, 10). Caspase-1–deficient mice are more suscep-
tible to E. coli infection than WT mice (19). NALP3 inflammasome 
(3–7) plays a critical role in the activation of caspase-1 in response 
to a variety of agonists, including bacterial toxins such as nigericin 
and mycotoxin as well as silica, asbestos, amyloid β, hemozoin, 
and extracellular ATP (20, 21). While it is clear that these agonists 
can promote NALP3 inflammasome activation, the molecular 
mechanisms linking microbial recognition and phagocytosis to 
the NALP3 inflammasome activation are not fully understood.
ATP activates P2X7 receptors, which act as potent initiators of 
NALP3 inflammasome and IL-1β cleavage and secretion (7, 22, 23). 
ATP can be released from host cells, acting as an autocrine DAMP 
to promote P2X7, NALP3 inflammasome, and caspase-1 activation 
(24). Here, we provide evidence for an additional molecular mech-
anism underlying host-pathogen interaction whereby ATP, acting 
as a PAMP, is released from viable bacteria and triggers P2X7, 
NALP3 inflammasome, and caspase-1 activation, which leads to 
IL-1β cleavage and secretion, thus regulating host immunity.
Heme oxygenase-1 (HO-1) is an inducible immunomodula-
tory (25) and cytoprotective enzyme (26–28) whose fundamental 
purpose is the degradation of heme to biliverdin, carbon mon-
oxide (CO), and free iron (29). HO-1 confers protection against 
a variety of pathologic conditions, including endotoxic shock 
and bacterial sepsis (25, 30–37). While CO appears to medi-
ate many of the salutary effects of HO-1 (38), its mechanism of 
action remains controversial. Chung et al. (32) and Desmard et 
al. (39) demonstrate that CO-releasing molecules (CO-RM) con-
fer host protection against infection, improving survival and pre-
venting end-organ failure in response to bacterial infection, an 
effect associated with direct bacterial clearance and killing (39, 
40). When produced physiologically, however, CO has no direct 
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large part independent of HO-1, but indicate that HO-1 may play 
a role in IL-1β processing. The dependency of IL-1β activation on 
HO-1 expression in response to bacteria was corroborated phar-
macologically. We saw similar effects in WT macrophages treated 
with tin-protoporphyrin-IX (Sn-PP-IX), which blocks HO-1 and 
HO-2, as well as the highly HO-1–selective inhibitor QC-15 (ref. 
43 and Figure 2A).
CO modulates IL-1β activation and substitutes for HO-1. HO-1 
generates biologically active CO that not only imparts antiinflam-
matory effects, but also augments immune responses against 
pathogens (44). We therefore next tested whether administration 
of exogenous CO could rescue HO-1 deficiency and reestablish the 
IL-1β response. Administration of exogenous CO to macrophages 
treated with the selective inhibitors of HO-1 was as follows: Sn-PP-IX 
or QC-15 or macrophages harvested from LyzM-Cre Hmox1fl/fl 
restored IL-1β secretion in response to bacteria in the presence 
of E. coli (Figure 2, A and B). Moreover, WT cells (either BMDMs 
or primary peritoneal macrophages [PMs]) showed an enhanced 
response to CO treatment with significantly greater IL-1β expres-
sion and caspase-1 activation compared with air-treated controls, 
suggesting that CO targeted in part the inflammasome machinery 
that generates active IL-1β (Figure 2C). We also tested an intracel-
lular pathogen, Salmonella typhimurium, which mediates IL-1β 
secretion via a NALP3 inflammasome–independent pathway and 
observed no difference in IL-1β secretion in Hmox1+/+ and Hmox1–/– 
macrophages, further suggesting that CO produced by HO-1 
specifically targets the NALP3 inflammasome pathway (Supple-
mental Figure 1A; supplemental material available online with 
this article; doi:10.1172/JCI72853DS1). Further, biliverdin, the 
other product of HO-1 activity, had no effect on bacteria-induced 
IL-1β expression (Supplemental Figure 1B). Finally, the effects of 
CO, like those observed with HO-1, were specific to IL-1β and not 
explained by global modulation of macrophage function because 
treatment with CO had no therapeutic effect on bacteria-induced 
TNF expression (Figure 2D).
HO-1 and CO are important in bacteria killing by macrophages. 
We next sought to study whether the effects of HO-1 and CO on 
IL-1β resulted in a functional effect on macrophage bacterial kill-
ing. IL-1β has been shown to influence bacterial phagocytosis 
(45). Bacterial killing was impaired in macrophages lacking HO-1 
as expected, an effect rescued by administration of exogenous 
CO (Figure 3A). Initial experiments employed the well-charac-
terized model of bacterial clearance in which bacteria growth is 
controlled by the addition of antibiotics. We found that addition 
of antibiotics 2 hours after infection to eliminate extracellular 
bacteria further amplified CO effects, with more rapid bacterial 
processing and less intracellular bacteria viability (Figure 3B). All 
subsequent experiments therefore were performed in the absence 
of antibiotics, which we considered a stronger correlate with our 
in vivo sepsis models where no antibiotics were used. The effects 
of CO on bacteria clearance were similar in mouse and primary 
human macrophages (Figure 3C). Strikingly, macrophages treat-
ed with CO were able to more effectively clear bacteria at concen-
trations that were otherwise unable to be cleared in air-treated 
control macrophages (Figure 3D). These effects mediated by CO 
were unrelated to direct bactericidal effects, as CO had no effect 
on bacterial growth in the absence of macrophages (Figure 3E). 
effect on bacterial growth and survival unless administered exog-
enously at supraphysiologic conditions (39). Inhaled CO has been 
tested in large animals and phase I human trials and approved for 
use at up to 10% to 12% carboxyhemoglobin (COHb). CO at simi-
lar regimens to those defined herein is currently being evaluated 
in phase II trials including studies of lung disease, organ trans-
plantation, and paralytic ileus (NCT00122694, NCT01523548, 
NCT00531856, NCT01050712; www.clinicaltrials.gov). Here, 
we propose that when produced endogenously by HO-1, CO acts 
as a key mediator of host defense used by the macrophages. This 
effect relies on the induction of ATP production and release by 
bacteria, regulating macrophage activation and promoting bacte-
rial clearance and host survival via the P2X7/NALP3 inflamma-
some and caspase-1/IL-1β signal transduction pathways.
Results
HO-1 controls bacteria-induced IL-1β expression by macrophages. 
Primary macrophages exposed to bacteria or endotoxin exhibit 
a marked increase in expression of HO-1 and proinflammatory 
cytokines such as IL-1β (32, 41) To test the role of HO-1 in IL-1β 
expression and activation in response to bacteria challenge, 
we used macrophages from Hmox1–/–and LyzM-Cre Hmox1fl/fl 
mice and WT macrophages infected with retroviral HO-1 
shRNA (Figure 1, A–C). Activation of IL-1β in response to bacte-
ria was largely dependent on the presence and activity of HO-1, 
as macrophages lacking HO-1 expression showed no increase 
in cleaved IL-1β and expressed lower pro–IL-1β versus controls, 
as measured by immunoblot or ELISA (Figure 1, A–C). Of note, 
commercial ELISA kits detect pro–IL-1β and thus underesti-
mate IL-1β processing by the NALP3 inflammasome pathway. 
The effects on IL-1β were specific and not explained by a global 
downregulation of macrophage activation in the absence of 
HO-1, as bacteria exposure induced a robust increase in TNF 
protein that was independent of HO-1 (Figure 1D). The effects 
of HO-1 on IL-1β were determined to be at the protein level 
(both the pro and cleaved forms of IL-1β). No statistical change 
in inflammasome component mRNA was observed between 
Hmox1+/– and Hmox1–/– macrophages in the presence or absence 
of bacteria (Figure 1E). Therefore, these data suggest that HO-1 
is involved in part in regulation of IL-1β expression and process-
ing via the inflammasome multiplex including NALP3 and the 
pro–IL-1β cleavage enzyme caspase-1.
To evaluate whether macrophages lacking HO-1 were deficient 
in their ability to activate the inflammasome, we treated macro-
phages with exogenous ATP, a well-characterized NALP3 stimu-
lus. BM-derived macrophages (BMDMs) isolated from Hmox1+/+ 
or Hmox1–/– were activated with bacterial LPS followed by treat-
ment with ATP. LPS treatment increased pro–IL-1β expression, 
which was then cleaved to IL-1β with the addition of ATP in both 
Hmox1–/– and Hmox1+/+ macrophages (Figure 1, F and G). Macro-
phages lacking HO-1 showed 25% to 30% less cleaved IL-1β com-
pared with WT cells, which was in part related to there being less 
pro–IL-1β. While Hmox1–/– BMDMs respond to LPS plus ATP with 
a significant increase in pro–IL-1β, they have been shown to also 
exhibit a delay in differentiation and are therefore less responsive 
to LPS due to lower expression of CD14 (42). Collectively, these 
data suggest that ATP-dependent macrophage activation is in 
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suggesting at least in part that IL-1β was participating in the bac-
tericidal function of macrophages (Figure 4, A and B). Treatment 
with CO was unable to augment killing in macrophages deficient 
in NALP3 or caspase-1 as compared with CO-treated Nalp3+/+ and 
Casp1+/+ macrophages (Figure 4, A and B). These findings further 
confirmed CO as promoting bacterial clearance by macrophages in 
part through a mechanism involving NALP3, caspase-1, and IL-1β 
activity. IL-1β is known to autoamplify macrophage activation in an 
autocrine or paracrine fashion (24, 46).
We and others have demonstrated that HO-1 deficiency 
results in impaired bacterial clearance (32), but provided no 
mechanism other then greater susceptibility to infection. The 
observed effects of CO on IL-1β cleavage/secretion and clearance 
Macrophage viability was also not altered by CO when tested in 
the presence of Enterococcus faecalis, where we observed 97% ± 
2% viability in air versus 93% + 4% in CO measured by trypan 
blue exclusion. Collectively, these data show that expression of 
HO-1 and its bioactive product CO are required in part for bacte-
rial clearance by macrophages.
CO increases bacterial-induced IL-1β secretion and bacterial clear-
ance by macrophages through a NALP3 inflammasome–dependent 
mechanism. The ability of macrophages to generate IL-1β is signifi-
cantly impaired in the absence of functional NALP3 and caspase-1 
(4). Macrophages harvested from both Nalp3–/– and Casp1–/– mice 
showed a significant impairment in ability to process and kill bac-
teria, which was most evident in caspase-1–deficient macrophages, 
Figure 1. Role of HO-1 on IL-1β release from bacteria-infected macrophages. (A–C) Representative immunoblots and ELISA for IL-1β in BMDMs or 
PMs treated with indicated bacteria (106 CFU/ml E. faecalis or 104 CFU/ml E. coli) for 10 hours. (A) Hmox1–/– (–) and Hmox1+/+ (+) BMDMs. (B) Immu-
noblot quantitation of PMs from LyzM-Cre Hmox1fl/fl and Hmox1fl/fl injected i.p. with E. coli for 2 hours (inset; Hmox1 expression in naive PMs). (C) 
Retroviral shRNA against HO-1 or latent membrane potential (LMP) control in BMDMs treated as in A. #P < 0.01, LyzM-Cre Hmox1fl/fl versus Hmox1fl/fl;  
**P < 0.001, *P < 0.05 versus LMP. Results represent average ± SD of 2 independent experiments in triplicate. (D) TNF ELISA in supernatants from 
BMDMs treated as in A. Results represent mean ± SD of 2 independent experiments in triplicate. (E) Real-time PCR of cDNA from cells treated as in 
A. Results represent mean fold change versus control ± SD of 2 independent experiments in triplicate. *P < 0.02. (F and G) IL-1β ELISA and immu-
noblot of BMDM supernatants from Hmox1+/+ and Hmox1–/– treated ± LPS (1 ng/ml) for 5 hours followed by 100 μM, 500 μM, or 1000 μM ATP. Data 
represent mean ± SD of n = 4–6 from 3 independent experiments. *P < 0.05.
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crine manner, as we also observed an increase in IL-1β receptor 
expression in E. coli–treated macrophages (Figure 4D). Given that 
CO exposure was initiated hours after bacteria administration, 
we elected not to focus on TLR receptors as potential mechanisms 
of action and targets for CO. Additionally, there was a significant 
reduction in bacteria-elicited IL-1β expression in BMDMs from 
Tlr2–/– and Tlr4–/– mice likely due to deficiencies in their ability to 
respond appropriately to bacteria wall components, resulting in 
less pro–IL-1β induction (47–49).
CO requires the presence of nucleotides to increase IL-1β in macro-
phages. Efforts to delineate the mechanism by which CO induces 
combined with the lack of effects in Nalp3–/– and Casp1–/– mac-
rophages prompted us to next test whether the enhanced IL-1β 
cleavage/secretion was participating in the effect exerted by CO 
on bacterial phagocytosis and/or clearance. The notion that CO 
promotes bacteria clearance via a mechanism that relies on IL-1β 
cleavage/activation was tested and reinforced by the observation 
that addition of recombinant IL-1β dose dependently increased 
E. faecalis clearance by macrophages similar to that observed with 
CO (Figure 4C). Further, the effect of CO on bacterial killing was 
abrogated using an anti–IL-1β neutralizing antibody (Figure 4C). 
It is therefore likely that IL-1β acts on macrophages in an auto-
Figure 2. Role of HO-1 and CO in IL-1β activation in macrophages. (A) IL-1β ELISA and immunoblot in BMDMs ± selective HO-1 inhibitors Sn-PP-IX and QC-15 ± CO 
started 4 hours after bacteria administration (106 CFU/ml) for 6 hours. Note that CO reversed the loss in HO-1 activity found in air treatment. *P < 0.05, air versus 
air + Sn-PP-IX; &P < 0.01, air versus CO; #P < 0.02, CO + Sn-PP-IX versus Sn-PP-IX. (B) Upper panel: IL-1β in BMDMs from the indicated mice ± E. coli (104 CFU/ml) 
± CO as above. Note that CO rescues the IL-1β response in LyzM-Cre Hmox1fl/fl that is absent in air-treated controls (comparing lanes 2 and 5). Lower panel: immu-
noblot showing disappearance of HO-1 in LyzM-Cre Hmox1fl/fl differentiated over 5 days in response to MCSF (20 ng/ml). Note that as the Lyz promoter becomes 
active, HO-1 expression decreases. (C) Representative IL-1β and active caspase-1 p20 immunoblots in BMDMs. CO was administered for 6 hours starting 4 hours 
following E. faecalis infection (106 CFU/ml). (D) TNF ELISA in supernatants from BMDMs infected with E. faecalis as above. All blots represent 2 to 3 independent 
experiments expressed relative to β-actin as loading control. All ELISA data represent mean ± SD of 2 to 3 independent experiments in triplicate.
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rophage lysosomal activity, in which CO exposure increased the 
number of bacteria contained in lysosomes (Figure 4B).
CO induces active release and production of ATP from bacteria. 
The requirement for ATP generation in the CO response direct-
ed us to first study whether the macrophages were the source for 
increased ATP. We observed that CO had no effect on intracellular 
ATP production by macrophages (0.82 ± 0.07 μM versus 0.96 ± 
0.15 μM air versus CO, respectively). CO also had no effect on ATP 
hydrolysis by ectonucleotidase activity (air plus E. faecalis: 213.5 ± 
45.41 nmols/min/mg protein versus CO plus E. faecalis: 226.61 ± 
33.3 nmols/min/mg protein). This implied that ATP was actively 
produced and released and/or prevented from being metabo-
lized by bacteria. ATP as a DAMP is known to influence NALP3 
inflammasome activation. CO exposure of heat-inactivated bac-
teria showed no increase in ATP levels or IL-1β secretion (data not 
shown), which suggested to us active release of ATP from bacteria 
in response to CO. While CO had no effect on bacterial growth 
(Figure 3E), it did induce a dose-dependent and rapid increase 
in bacteria-derived ATP versus air-treated controls, as assessed 
by time-lapse imaging and colorimetric analyses (Figure 5, A and 
B). The amount of ATP generated by the bacteria in response to 
CO was similar in magnitude to levels of ATP released from dying 
cancer cells, which contribute critically to NALP3 inflammasome 
IL-1β cleavage/activation and bacterial clearance directed us 
initially to test the effect of CO on well-established activators of 
the NALP3 inflammasome. CO can induce mitochondrial ROS 
generation in macrophages, an effect that could enable NALP3 
inflammasome activation (50–52). E. faecalis induced a modest 
but significant ROS generation in macrophages, an effect that was 
not further modulated by CO (Supplemental Figure 2, A and B). 
This suggested to us that the mechanism by which CO modulates 
the NALP3 multiplex activation does not involve modulation of 
ROS production in bacteria-treated macrophages (52). It is likely, 
however, that the elevated ROS do contribute to bacterial killing in 
the lysosomal compartment. Inhibition of cathepsin B, a protease 
known to activate NALP3 inflammasome, also did not modulate 
CO-induced IL-1β cleavage/secretion (Figure 4E).
Somewhat surprisingly, the effects of CO were dependent on 
the presence of ATP as well as on a functional cytoskeletal appara-
tus. We augmented ATP catalysis using apyrase and used cytocha-
lasin B to block actin microfilament formation, and both of these 
agents suppressed the ability of CO to induce IL-1β secretion (Fig-
ure 4E). Remarkably, neither apyrase nor the cytochalasin B inhibi-
tor completely returned IL-1β to basal levels in air-treated controls, 
suggesting other mechanisms in place, including elevated expres-
sion of pro–IL-1β. These data corroborate the effects of CO on mac-
Figure 3. CO enhances bacterial killing by macrophages. (A) CFU in BMDM lysates ± E. coli (104) administered for 1 hour followed by exposure to CO or air 
for 6 hours. #P < 0.05, CO versus air in LyzM-Cre Hmox1fl/fl and Hmox1fl/fl macrophages; *P < 0.05, LyzM-Cre Hmox1fl/fl versus Hmox1fl/fl macrophages. (B) 
Bacterial counts in BMDM lysates ± E. coli administered for 2 hours followed by addition of penicillin/streptomycin ± CO for 6 hours. Results represent 
average ± SD of 2 independent experiments in triplicate. *P < 0.001, CO versus air. (C) CFU in supernatants of mouse BMDMs or primary human peripheral 
blood monocytes (hMo) + E. faecalis (106) for 1 hour prior to CO (white bars) or air (black bars) administration for an additional 4 hours. *P < 0.007;  
**P < 0.01, CO versus air (C). (D) Growth kinetics of E. faecalis in BMDM supernatants ± CO measured as absorbance at 600 nm. Blue indicates 102, red indi-
cates 106, and violet indicates 1010 CFU/ml. CO, dotted lines; air, solid lines. Data represent mean ± SD of n = 3/group/time point. *P < 0.005; **P < 0.05, 
versus air at the same bacterial concentration and time point. (E) Growth kinetics of E. faecalis in the medium in the presence or absence of CO. Results 
represent mean ± SD from 3 independent experiments. Note: similar effects of CO on growth were observed with E. coli.
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Figure 4. NALP3 is targeted by CO to enhance IL-1β expression and mediate macrophage bacteria killing. (A) CFU in WT (air), Nalp3–/–, and Casp1–/– BMDM 
supernatants infected with E. faecalis ± CO. *P < 0.01 versus air-treated controls. (B) Quantitation and representative images (inset) of cells positive for 
lysozyme (red) and E. faecalis in BMDMs from WT (air), Casp1–/–, and Nalp3–/– mice. Nuclei are stained blue. BMDMs were treated with E. faecalis for 1 hour 
followed by 4 hours of CO (white bars) or air (black bars). **P < 0.001, CO versus air; #P < 0.05, Nalp3–/– versus WT; &P < 0.05, Casp1–/– versus WT. Original 
magnification, ×40. (C) Bacterial counts in BMDM treated with supernatants ± E. faecalis for 1 hour and then treated ± anti–IL-1β or IL-1β recombinant 
protein. CO (white bars) or air (black bars) was applied as above. *P < 0.001, CO versus air; **P < 0.01, CO versus air. Results represent mean ± SD of 2 to 
4 independent experiments in triplicate. (D) Flow cytometry in BMDMs treated with E. faecalis for 1 hour or BMDMs with antibody against ILRa-APC. IgG-
APC as negative control. Mean ± SD from 3 independent experiments. *P < 0.05, E. faecalis versus control (C) or IgG. (E) IL-1β levels in E. faecalis–treated 
BMDM supernatants as above for 4 hours followed by 1 hour treatment with cathepsin B inhibitor, cytochalasin B, or apyrase. Cells were then exposed to 
CO or air for 4 hours. Results are presented as percentage of control to account for vehicle effects and represent mean ± SD of 3 independent experiments 
in duplicate. *P < 0.05, comparing CO versus air in both the vehicle-treated control group and the cathepsin B inhibitor-treated group.
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activation via a mechanism involving the ATP P2 receptor (53). 
Important here is that the ATP generated by bacteria was present 
at concentrations ranging from 3 to 5 μM in CO versus 1 to 2 μM 
basally and remained elevated and continuously generated by the 
bacteria when CO was present. This increase in ATP in response 
to CO likely underestimates the local concentrations at the mac-
rophage cell surface, where ATP is released by the bacteria and 
likely continues inside the phagosome. We next asked whether 
bacteria-derived ATP contributed to modulation of macrophage 
activation by CO. We measured bacterial ATP release and binding 
to macrophages in response to CO by loading E. coli with radiola-
beled phosphate (32P) and measuring the amount of 32ATP bound 
to P2X7 receptors immunoprecipitated from macrophages. A sig-
nificant increase in 32ATP binding to P2X7 was observed in CO 
versus air-treated macrophages (Figure 5C). There was no bind-
ing of ATP in P2x7–/– macrophages (Figure 5D), suggesting that this 
is indeed a receptor for ATP originating in the bacteria and then 
binding to macrophages. To test whether endogenous CO arising 
from HO-1 exerted the same effects on bacteria, HO-1 was maxi-
mally induced in macrophages in response to LPS, and the con-
ditioned medium, when rapidly transferred to 32P-loaded bacteria 
cultures, showed a significant increase in 32ATP formation (Figure 
5E). 32ATP was captured with a bacterial ATP-binding protein, 
which was subsequently immunoprecipitated and subjected to 
thin-layer chromatography; the radiolabel was densitometrically 
quantitated. Importantly, blockade of HO-1 with QC-15 in this 
scenario completely abrogated the 32ATP increase (Figure 5E). 
Finally, to demonstrate a functional impact of the elevated ATP, 
macrophages were treated with exogenous ATP, which recapitu-
lated that observed with CO in enhancing bacterial clearance (Fig-
ure 5F). Collectively, these data support a mechanism by which 
pathogens are recognized and destroyed by the host that involves 
activation of macrophages by ATP (54, 55).
To further strengthen the concept that bacteria-derived ATP 
was the DAMP responsible for macrophage activation, we next uti-
lized an E. coli strain lacking the ATP synthase subunit A (ΔatpA). 
Figure 5. Effects of CO on bacteria-derived ATP generation and macrophage-killing response. (A) ATP generation by E. faecalis (106) ± CO for 1 hour mea-
sured colorimetrically (inset) or fluorometrically. (B) ATP fluorescence in supernatants from E. coli (104) treated for 6 hours ± CO. *P < 0.05; **P < 0.001. (C 
and D) Interaction between E. coli–derived 32ATP and immunoprecipitated BMDM P2X7 receptor from WT and P2rx7–/– mice (D) treated with supernatant from 
CO-exposed 32ATP-producing bacteria. Neg, IgG control; A, ampicillin control. *P < 0.03; #P < 0.05, CO versus air. (E) 32ATP-producing bacteria supernatant 
exposed to BMDMs where HO-1 was induced by LPS to increase endogenous CO by HO-1 ± QC-15 to block HO-1. *P < 0.01, LPS versus control (C); #P < 0.05, 
LPS versus LPS + QC. (F) Bacterial counts in BMDM supernatants infected with E. faecalis for 1 hour, then ± ATP (50 μM) for an additional 6 hours. *P < 0.05. 
(G) ATP in supernatants of WT E. coli MG1665 or ΔatpA E. coli (104) treated 30 minutes with CO or air expressed as fold change to account for proliferation 
rate differences. Data represent mean ± SD of 3 experiments in triplicate. *P < 0.02, CO + M1655 versus air + M1655. (H) Immunoblot with antibodies against 
IL-1β lysates of WT or mutant E. coli–treated BMDMs ± CO as above. (I) Bacterial counts expressed as fold change due to differences in proliferative rates. 
BMDMs were infected for 1 hour, then treated ± CO for an additional 6 hours. **P < 0.01, CO versus WT E. coli (102). *P < 0.05, CO + ΔcyoB versus air + ΔcyoB; 
&P < 0.04, CO + Δcyd versus air + Δcyd. (J) WT or mutant E. coli growth ± CO. Results represent mean ± SD from 3 independent experiments.
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macrophage P2 receptors triggering NALP3/IL-1β/inflamma-
some–dependent bacterial clearance (57).
CO increases bacteria-derived ATP generation in vivo. The 
effects of CO on bacterial ATP production were recapitulated in 
vivo in mice infected i.p. with WT E. coli. We took advantage of 
the fact that luciferase requires ATP to metabolize luciferin and 
used the luciferase signal intensity as an indirect measure of ATP. 
Mice exposed to CO showed a significantly enhanced luciferin sig-
nal versus air-treated controls, demonstrating the presence of ATP 
required for luciferase activity (Figure 6, A and B). The luciferin 
signal was localized to the site of bacteria inoculation in the peri-
toneal cavity and measured 1 hour after CO, when the amount of 
bacteria would still be similar between air and CO. These results 
suggested that the highly diffusible CO accessed the peritoneal 
cavity and interacted with the bacteria to compel the 2- to 3-fold 
increase in ATP levels in a manner similar to that generated by 
bacteria in response to CO in vitro.
CO promotes IL-1β secretion via K+ channel–dependent activation 
in macrophages. Given that CO is reported to modulate K+ chan-
nel activity via ATP purinergic receptor signaling (58, 59), we 
hypothesized that CO modulated NALP3 inflammasome activa-
tion through modulation of an ATP-dependent K+ channel that 
likely involves one or more P2 receptors (7, 20). First, we mea-
sured intracellular K+ concentrations in macrophages in response 
to ATP and, as expected, observed a marked decrease in intracel-
lular K+ levels. Macrophages treated with either bacteria or CO 
alone had little effect on intracellular K+ concentrations (Figure 
7A). In contrast, macrophages treated with E. coli (WT or MG1655) 
plus CO showed a decrease in intracellular K+ equivalent to that 
observed with ATP alone (Figure 7A). Employing the selective 
K+ channel inhibitor tetraethylammonium (TEA), we tested the 
relative contributions of ATP and K+ channel activity on NALP3 
inflammasome activation in response to CO. Mice infected with 
E. faecalis were treated with or without CO and with or without the 
addition of TEA. PMs were harvested and assessed for caspase-1 
This strain survives on alternative, weaker ATP-generating sys-
tems. This mutant allowed us to study the molecular target under-
lying the effect of CO on bacteria-derived ATP. Macrophages were 
infected with the ΔatpA E. coli or with the E. coli MG1655 control 
strain and treated with or without CO. As shown in Figure 5G, 
unlike what occurred in the MG1655 control strain, CO was unable 
to increase ATP levels over baseline in the ΔatpA mutant, dem-
onstrating that CO promotes production of ATP via a mechanism 
that in part requires a fully functional ATP synthase. Moreover, 
macrophages infected with ΔatpA in the presence of CO generated 
very little to no cleaved IL-1β (Figure 5H). We used 2 additional 
E. coli mutants, ΔcyoB and ΔcydB. These mutants lack the indi-
cated cytochrome oxidase in the bacteria, and it is these heme- 
containing oxidases that are known to be targets for CO (64). When 
macrophages were treated with these 2 strains in the presence of 
CO, we observed an effective increase in IL-1β in the ΔcyoB strain 
that correlated with augmented clearance, but no effect of CO on 
either IL-1β cleavage or bac-
teria clearance in the ΔcydB 
strain (Figure 5, H–J). Impor-
tantly, both pro and cleaved 
IL-1β were markedly reduced 
in ΔcydB. From these data, 
we conclude that CO targets 
and perhaps binds to heme in 
the oxidase of ΔcydB to com-
pel ATP generation much 
like that observed in the ATP 
synthase mutant. Absence 
of either protein resulted in a 
loss in CO effects on IL-1β and 
bacteria killing. While each of 
the strains exhibited slightly 
different growth rates, these 
were not affected by exposure 
to CO (Figure 5J). Collectively, 
these data strongly support the 
notion that bacteria-generated 
ATP can bind and activate 
Figure 6. CO increases ATP levels in bacteria-infected mice. (A and B). ATP 
measured by IVIS bioluminescence or fluorescence in mouse peritoneal 
lavages. Mice (n = 4/group) were infected with E. coli (109) for 1 hour followed 
by CO for 1 hour. ATP levels were imaged and quantitated 30 minutes after 
injection of luciferase. *P < 0.05, CO versus air. The stronger signal intensity 
reflects increased ATP levels evidenced by greater luciferase activity.
Figure 7. CO modulates potassium flux in vitro and in vivo in macrophages. (A) Intracellular potassium (K+) levels 
measured fluorometrically in BMDMs infected with E. coli (104) ± CO. ATP (200 μM) was used as a positive control. 
Note that both ATP and CO + E. coli decreased intracellular K+ fluorescence, suggesting a K+ efflux. *P < 0.0001, 
ATP versus WT; #P < 0.001, M1655+CO versus WT; &P < 0.001, M1655 or CO versus WT. White bars, air; black bars, 
CO. (B) IL-1β ELISA of peritoneal lavage fluid from mice treated ± E. faecalis (106) ± K+ channel inhibition with TEA 
± CO. CO was started 1 hour after infection and continued for 1 hour. *P < 0.01 CO versus control (C). All results 
represent mean ± SD of 2 to 4 independent experiments with n = 3–6/group.
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cecal ligation and puncture (CLP) model of sepsis. CO adminis-
tered 1 hour after CLP increased survival to 60% compared with 
5% in air-treated controls (Figure 8G).
CO requires NALP3 and caspase-1 to impart protective effects 
against lethal infection and is able to rescue mice deficient in HO-1. 
Our in vitro evidence supporting a role for the NALP3 inflamma-
some on the CO effects led us to next inoculate Nalp3–/– and Casp1–/– 
mice with E. faecalis and measure clearance. Mice deficient in 
either protein were unresponsive to CO in the lethal sepsis model 
or bacterial killing assay, and Casp1–/– mice showed a significant 
deficit in the ability to kill bacteria with or without CO present 
(Figure 8, H and I). These data suggest that CO requires activation 
of caspase-1 and the resulting IL-1β release to promote bacterial 
clearance, confirming our in vitro observations (Figure 4).
Animals lacking HO-1 activity are exquisitely sensitive to bac-
terial infection (32, 37). Importantly, CO was able to rescue a sig-
nificant percentage of inoculated LyzM-Cre Hmox1fl/fl mice (HO-1 
absent in myeloid cells) and WT mice in which HO activity was 
inhibited with Sn-PP-IX (Figure 8, J and K).
Discussion
Pathogen recognition by germline-encoded PRR is a paramount 
requirement for host protection against infection (60, 61). 
However, PRR do not sense the metabolic activity status of the 
pathogen recognized and hence evaluate its potential pathoge-
nicity. Pathogen detection and elimination must be metaboli-
cally efficient, highly specific, and complete, with indispens-
able secondary and perhaps tertiary regulatory checkpoints. 
We propose that when generated endogenously by HO-1, CO 
is deployed by the host to reveal the presence of metabolically 
functional bacteria, revealed by the generation of bacterial ATP, 
which amplifies the macrophages’ killing machinery. More-
over, we demonstrate that under physiologic conditions, CO 
is required for appropriate activation of the NALP3 inflamma-
some, leading to caspase-1 activation via selective triggering of 
a K+ channel by bacterial ATP, which results ultimately in secre-
tion of IL-1β, bacterial phagocytosis, and killing. These effects 
are likely not related to decreased oxygen availability because 
similar immunomodulatory effects on macrophage activation 
were not observed under hypoxic conditions (25). Paradoxi-
cally, CO improves oxygenation during ischemic stress (62).
Under homeostatic conditions, HO-1 is expressed mainly in 
hematophagocytic macrophages in the red pulp of the spleen, 
being strongly induced in all other tissue-resident macrophages 
once these sense the presence of bacteria and other stress-related 
conditions (29). Presumably, this allows HO-1 to confer a natural 
mechanism for innate immune cell regulation in the context of 
bacterial recognition. In keeping with this notion, HO-1 deletion 
increases sensitivity to bacterial infection, an effect associated 
with a marked deficit in the ability of the macrophages to evoke an 
archetypical bacterial clearance response. As demonstrated herein, 
this impairment in the macrophage response is driven by defective 
IL-1 processing via the NALP3 inflammasome/caspase-1 pathway, 
revealing an unsuspected mechanism by which macrophages using 
the HO-1/CO system sense the metabolic status of pathogens, 
namely, their capacity to produce ATP in response to this highly 
diffusible gas. This would then allow the macrophages to modu-
cleavage and IL-1β expression. TEA suppressed the ability of CO to 
increase caspase-1 activation and IL-1β secretion compared with 
controls linking K+ channel to inflammasome activity. (Figure 7B). 
The inability of TEA to block IL-1β expression to levels below that 
observed with E. faecalis alone suggests other ATP-dependent, 
non–K+ channel–mediated mechanisms involved in the activation 
of IL-1β, such as P2Y receptors (57). Collectively, these findings 
speak to the selectivity of CO in modulating IL-1β via P2 receptor 
signaling, perhaps suggesting differences in ATP affinity for each 
purinergic receptor.
CO protects against sepsis-induced multiorgan failure in mice. 
To test our in vitro observations in a clinically relevant experi-
mental model of bacterial infection in vivo, we inoculated mice 
i.p. with a lethal dose of E. faecalis prior to therapeutic admin-
istration of inhaled CO. Caspase-1 cleavage and IL-1β secretion 
were measured in peritoneal exudates. We observed a significant 
time-dependent induction of IL-1β cleavage/secretion in PMs in 
response to bacteria, an effect enhanced by inhaled CO (Figure 
8, A–C). Of note, IL-1β cleavage/secretion was measured in total 
peritoneal exudates, which likely involves cell types other than 
macrophages. While the effects of CO on IL-1β expression and 
corresponding caspase-1 cleavage were evident in peritoneal 
leukocytes, this was not associated with a systemic increase in 
IL-1β, suggesting that CO acts at the primary site of infection 
targeting live bacteria, compelling their release of ATP, which in 
turn drives increased IL-1β secretion by activated macrophages. 
Moreover, CO also promoted more rapid resolution of inflam-
mation, as suggested by the more rapid decrease in IL-1β expres-
sion, which occurred as early as 4 hours after infection compared 
with that of controls treated with air at the same time point. The 
more rapid resolution of the infection correlated with a greater 
than 50% increase in bacterial clearance over controls as well as 
improved survival and inhibition of multiorgan failure (Figure 8). 
CO protected against sepsis-induced gut epithelial cell sloughing 
in the colon and acute liver injury as assessed by reduced levels 
of serum transaminases (ALT) (Figure 8, D and E). Acute kidney 
injury was also abrogated. Elevated serum blood urea nitrogen 
(BUN) levels as a measure of kidney damage were lower in CO-
treated mice compared with air-treated controls (97.3 ± 16.3 mg/dl 
in air versus 32.0 ± 19.4 in CO-treated mice, P < 0.02; normal 
BUN = 18–29 mg/dl). Real-time IVIS imaging using chemilumi-
nescent E. coli (Xen 14) corroborated the ability of CO to augment 
bacterial clearance (Figure 8F). Leukocyte infiltration into the 
peritoneal cavity in response to bacterial administration showed 
an increase in neutrophils (PMN) at 4 hours after infection (10.4 
± 1.1 × 106 versus 1.3 ± –0.3 × 106 in untreated controls P < 0.02). 
PMN cell infiltration was modestly reduced in CO-treated mice 
(6.1 ± 1.9 × 106) over the same time interval, correlating with the 
decreased bacterial counts and modulation of the inflammatory 
response (Figure 8, A and F).
Mice infected i.p. with E. faecalis and exposed to air suc-
cumbed to lethal septic shock (75% mortality) within 24 to 48 
hours (Figure 8G). Inhaled CO, when initiated 1 hour after infec-
tion, resulted in 100% survival, while exposure to CO initiated as 
long as 6 hours after bacterial injection resulted in 60% survival 
(Figure 8G). The experiments were stopped at 4 days, which was 
considered long-term survival. CO also conferred protection in a 
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Figure 8. CO acts therapeutically to inhibit lethal sepsis via the inflammasome. (A) IL-1β in peritoneum from mice infected with E. faecalis (109 CFU) for 
1 hour ± CO. Data represent mean ± SD of n = 6/group in triplicate. *P < 0.01; #P < 0.05, CO versus air. (B) Immunoblot of cleaved caspase-1 and IL-1β in PM 
lysates from mice infected with E. faecalis for 1 hour prior to 1 hour treatment with air or CO. Representative blot from 3 independent experiments. (C) 
Immunoblots of macrophages lysates from mice treated as in B. (D) ALT in infected mice treated as above. Results represent mean ± SD (n = 4–6/group) 
from 3 experiments. *P < 0.001, CO versus air. (E) H&E staining 8 hours after E. faecalis ± CO; 6 to 10 images per animal. Arrows indicate lesions. Original 
magnification, ×20. (F) Bacterial counts in peritoneal lavagates. Inset: IVIS images. Results represent mean ± SD of 6 to 8/group. *P < 0.05; **P < 0.01. 
(G) Survival in mice injected with lethal E. coli (1010 CFU, i.p.) or CLP ± 4 hours CO initiated 6 hours later. P < 0.02, air + CLP versus CO + CLP; P < 0.02, air 
+ E. coli versus CO + E. coli. (H) Survival of WT and Nalp3–/– mice treated as in G with or without CO (started 1 or 6 hours after bacteria). CO was unable to 
protect Nalp3–/– mice (P < 0.01). (I) Bacteria counts in peritoneum of E. coli–infected mice. Results represent mean ± SD of 4 to 6/group repeated twice.  
*P < 0.03, CO versus air; #P < 0.05, Casp1–/– versus Casp1+/+ in both air and CO-treated mice. (J) Survival ± Sn-PP-IX to block HO-1 then ± 4 hours CO begin-
ning 1 hour after bacteria. P < 0.05, 10/group. (K) Survival of indicated mice ± CO as in G. P < 0.03. n = 10–30/group.
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intracellular, results in activation of alternative macrophage clear-
ance pathways directed by an intracellular CO-ATP axis and depen-
dent on NLRC4 (67). HO-1 is also localized and active in high levels 
intracellularly in the endoplasmic reticulum and mitochondria.
In summary, we unveil a unique and evolutionarily conserved 
paradigm for innate sensing of metabolically active microbes in 
which CO, deployed from innate immune cells, acts on behalf of 
the host and serves as a metabolic scout for the presence of live 
bacteria. Should it confront viable, pathogenic bacteria, CO binds 
to its respiratory heme complexes, inducing the release of ATP, 
a danger signal that activates a lytic response in innate immune 
cells. Collectively, we describe a compelling model (Figure 9) by 
which the macrophage and microbe communicate in a way that 
ensures host survival (Figure 9). When acting in the context of PRR 
ligation, CO participates in the efficient marking of pathogens, 
unleashing a cytotoxic response aimed at pathogen clearance.
Methods
Bacteria isolation and propagation
E. coli (DH5α strain, ATCC), E. coli Xen 14 (chemiluminescent EPEC 
WS2572–parental strain, Caliper Life Sciences), Salmonella enterica 
(S. typhimurium) (ATCC), Mtb-BCG (provided by William Bishai, 
Johns Hopkins University, Baltimore, Maryland, USA), and E. faecalis 
or E. coli (single colony isolated from mouse intestinal flora) were 
used. Additionally, E. coli MG1655 and knockout strains (ΔatpA, 
ΔcydB, ΔcyoB) originally acquired from the Keio library were provided 
by Bernard Strauss (Massachusetts Institute of Technology [MIT], 
Cambridge, Massachusetts, USA). A single colony of each type of 
bacteria was isolated from the agar plate and cultured overnight in 
an orbital shaker in LB medium (E. coli, E. faecalis), nutrient broth 
(S. typhimurium), or in Lowenstein Jensen Medium with Mycobacteri-
al Supplement (M. bovis, Sigma-Aldrich). After determination of an ini-
tial absorbance at 600 nm, dilutions were prepared in antibiotic-free 
medium to permit using macrophages at indicated doses. Samples of 
dilutions were dilution plated to determine CFU (CFU/ml). For in vitro 
experiments, the amount of bacteria averaged 106 CFU/ml (MOI of 
40–50) for E. faecalis and 104 CFU/ml (MOI of 1–10) for E. coli unless 
otherwise indicated. For infection in vitro, no antibiotics were used 
unless indicated and macrophages were washed twice with PBS prior 
to infection to remove any residual antibiotics. We performed pilot 
dose escalation experiments using E. faecalis and E. coli and found that 
doses of 104 and 106 CFU/ml of E. coli and E. faecalis, respectively, did 
not induce macrophage death at up to 10 hours (crystal violet exclu-
sion, data not shown) and stimulated pro–IL-1β cleavage (Figure 1); the 
bacteria were killed by macrophages (Figure 3. Higher doses of bacte-
ria killed macrophages by 10 hours. Therefore, in our in vitro studies, 
we used either 106 or 104 CFU/ml of E. faecalis and E. coli, respectively. 
Under these conditions, induction of pro–IL-1β occurs at between 4 
and 6 hours. These amounts of bacteria in culture correlated with an 
overwhelming infection in the animal models.
Cell culture
BMDMs from mice were harvested and differentiated as previously 
described (68). For each experiment, cells were seeded at a density of 
1 to 2 million per 60 mm plate. PMs were isolated by washing perito-
neum of mice with 1 ml, 1× PBS. Cells were then centrifuged and resus-
late activation of the NALP3 inflammasome/caspase-1 pathway, 
achieving pathogen clearance while limiting tissue damage.
CO binds to heme-containing bacterial respiratory complexes 
located on the outer membrane to produce ATP, leading to inflam-
masome activation and ultimately bacterial clearance. While ATP 
was thought to arise from intracellular stores following host cell 
death (63), we now describe how CO compels bacteria to generate 
this second signal, which permits more efficient elimination ver-
sus direct bacterial lysis. In the absence of bacterial ATP, the local 
inflammation elicited by metabolically inactive bacteria or endotox-
in is resolved without instigation of a nonspecific immune response.
Spectral analyses of the E. coli cytochrome complex showed 
that CO binds to the heme component of the bacterial subunit 
1 oxidase, which is involved in aerobic oxidative respiration and 
contributes to the generation of ATP (64). The cydB terminal 
oxidase, which preferentially functions as a proton motive force 
under anaerobic conditions, when absent in the ΔcydB bacte-
ria, abrogated the ability of CO to regulate IL-1β and bacterial 
clearance. Indeed, basal expression of pro–IL-1β was strikingly 
reduced in the cydB mutant and markedly amplified in the ΔcyoB 
knockout, where cydB oxidase was likely overexpressed in com-
pensating for the absence of cyoB. In addition to the necessary 
proton motive force, interfering with the ATP synthase, which 
lies further downstream of the oxidases toward the generation 
of ATP, also negated the effects of CO on bacterial clearance and 
IL-1β expression (Figure 5). It is well established that ATP acts 
through macrophage purinergic receptors (both P2X and P2Y) to 
achieve NALP3 inflammasome activation (7, 57). A significantly 
reduced inflammasome response leads to inefficient release 
of IL-1β, compromising bacterial clearance, which we demon-
strate can be rescued in macrophages with addition of recombi-
nant IL-1β (Figure 4). This paradigm may reflect expression of 
IL-1β, which functions to enhance macrophage activation. This 
enhanced activation has been reported to influence the phago-
cytic and/or metabolic state of the macrophage (65). Hedl and 
Abraham demonstrated that IL-1β can auto activate MAP kinas-
es and NOD2 responses in macrophages (63). We find that IL-1β 
neutralization affects the killing capabilities of the macrophages. 
Indeed, work by Kanangat et al. suggests that low doses of IL-1β 
(up to 250 pg/ml) inhibit bacterial growth while higher levels of 
IL-1β promote growth (66).
We found a unique metabolic interaction between host and 
microbe and put forth an efficient 2-hit system for the recognition 
by innate immune cells of metabolically active microbes, presum-
ably acting as the earliest immune response against pathogen 
invasion. Were only one signal required, host macrophages would 
likely exist in an ongoing unfettered activation state, particularly 
in the peritoneum, gastrointestinal tract, and the liver, where 
intestinal endotoxin levels fluctuate with intestinal microbes in 
close proximity. In such instances, mounting a full inflammatory 
response would be metabolically costly, inefficient, and potential-
ly detrimental to the organism.
Our observations are applicable to Gram-positive and -negative 
bacteria as well as Mycobacterium bovis bacillus Calmette-Guérin 
(Mtb-BCG), but interestingly, were not apparent in response to 
S. typhimurium. Perhaps this is explained in part by alternative kinet-
ics of the response or by the fact that Salmonella, being primarily 
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Animals
Nalp3–/–, Casp1–/–, and control WT animals were generated as previously 
described (23). C57BL/6 mice as well as type 1 Il1r–/–, Tlr4–/–, and LyzM-
Cre recombinase animals were purchased from Jackson Laboratories. 
Tlr2–/– mice were provided by Hong Jun Wang (BIDMC). Hmox1–/– 
mice were generated as previously described (3). Hmox1fl/fl mice were 
provided by the RIKEN BRC through the National Bio-Resource Proj-
ect, Japan. The characterization of these mice was previously reported 
(4). Hmox1fl/fl mice were bred with LyzM-Cre mice(Jackson Laborato-
ries), and LyzM-Cre Hmox1fl/fl homozygotes were identified by geno-
typing (70). In all experiments, animals were treated with bacteria for 
1 to 6 hours at the indicated concentrations in a volume of 500 μl i.p. 
prior to being exposed to CO (250 ppm). The amounts of bacteria were 
selected from a combination of preliminary dose-ranging studies and 
literature review (32, 71, 72). The amount of bacteria administered 
ranged from 104 to 1010, depending on whether the studies were sub-
lethal or lethal in design, to assess relevant readouts associated with 
the pathophysiology of sepsis. Doses are listed in Methods and figure 
legends. Sn-PP-IX or saline vehicle as control was used at 50 mg/kg 16 
and 5 hours prior to bacterial infection.
CLP. Male C57BL/6 mice (Jackson Laboratories) were at ages 
6 to 8 weeks and weighed 20 to 25 g. Briefly, animals were anesthe-
tized with pentobarbital (70 mg/kg, i.p.); a 1- to 2-centimeter midline 
laparotomy was performed and the cecum identified. Stool was then 
milked to the tip of the cecum and ligated 1 centimeter from the tip 
with 2-0 silk. The cecum was then perforated with a 22-gauge needle 
and returned to the abdomen. The musculature and skin were closed 
with a running 2-0 silk suture. Sham animals underwent laparotomy 
and bowel manipulation without ligation or perforation.
Histopathology. Liver and small intestine were harvested, fixed in 
10% paraformaldehyde, and stained with H&E. Images were captured 
as previously described (28, 35).
ATP measurement
ATP in samples was determined colorimetrically and fluorometrically 
using commercial assay kits (BioVision Inc). Macrophages were inocu-
lated with bacteria for 4 hours, followed by treatment with CO or air. 
Supernatants were cleared by centrifugation at 500 g for 5 minutes 
prior to analyses. In similar experiments, bacteria were viewed with 
a Zeiss Axiovert Apotome Microscope and fluorescence measured 
in real time in the presence of air or CO (250 ppm). For colorimetric 
determination of ATP, 0.5 ml of reaction mix was directly applied to 
the bacteria-coated plates. Plates were treated with or without CO for 
1 hour, and the development of color (pink) indicated ATP production.
IVIS. In vivo imaging of ATP production was measured in the 
Longwood Medical Small Animal Imaging Facility (SAIF), BID-
MC, indirectly using luciferase (Sigma-Aldrich). ATP generation in 
response to E. coli infection was measured in the peritoneum with or 
without CO after injection of equal amounts of D-luciferin and lucif-
erase (20 mg/kg each i.p., Sigma-Aldrich). The intensity of biolumi-
nescence corresponded indirectly to ATP levels. ATP is required for 
luciferase activity, and thus an increase in luciferase signal reflects in 
part the available ATP. ATP was also determined in cell-free peritoneal 
lavagates using the fluorescent assay kit as described above.
32ATP interaction with P2X7 and bacterial ATP-binding protein. 
E. coli were cultured in phosphate-free medium supplemented with 
0.2 mCi 32P for 2 hours. As a control, a separate culture of bacteria 
pended in RPMI medium (Life Technologies) with 10% FBS (Atlanta 
Biologicals). PMs were used for experiments after 24 hours of culture 
in vitro. In all experiments, BMDMs or PMs were challenged with 
the indicated bacterium ± CO (250 parts per million [ppm]) or air as 
described previously (69).
Retroviral transduction of BMDMs with shRNA. BM cells were iso-
lated and cultured in the medium containing SCF (100 ng/ml), IL-6 
(10 ng/ml), and IL-3 (6 ng/ml) (PeproTech) for 24 hours. Retroviral 
microadapted shRNA was prepared as described (68). Cells were 
transduced 12 hours with retroviruses in medium containing Poly-
brene (8 μg/ml, Sigma-Aldrich). Twenty-four hours later, MCSF (Pep-
rotech) was added for differentiation into macrophages as above.
Reagents
TEA (Calbiochem; Millipore), a nonspecific BK channel inhibitor, was 
dissolved in water. Mice were treated with TEA (30 mg/kg, i.p.) 30 
minutes before treatment with CO or air. In vitro TEA (1 μM), NAC 
(20 mM), cathepsin B inhibitor (10 μM), apyrase (5 U/ml), cytocha-
lasin B, (5 μg/ml), and LPS (10 ng/ml) were purchased from Sigma-
Aldrich. QC-15 (25 μM) was provided by D. Nakatsu (Queen’s Univer-
sity, Kingston, Ontario, Canada). Sn-PP-IX (30 μM), and biliverdin 
(50 μM) were purchased from Frontier Scientific. Recombinant IL-1β 
(200–1000 pg/ml, R&D Systems) or ATP (50 μM) was applied 1 hour 
before CO treatment. Anti-mouse neutralizing IL-1β/IL-1F2 Abs (100 
ng/ml, R&D Systems) were applied 15 minutes prior to CO treatment.
Phagolysosome staining. BMDMs were treated with bacteria as 
described above for 1 hour, and CO or air was then applied for 4 hours. 
For the last 30 minutes of treatment, cells were loaded with Lyso-
Tracker Red DND-99 (Molecular Probes; Invitrogen). Hoechst stain-
ing (Molecular Probes; Invitrogen) was applied on 2% PFA-fixed cells. 
Pictures were taken under ×40 magnification on a Zeiss Apotome 
Axiovert Fluorescence Microscope.
Figure 9. Schematic depicting a proposed mechanism of action for HO-1 
and CO in bacteria recognition and activation of innate immune defense 
machinery. As a highly diffusible gas, HO-1 is induced by endotoxin (LPS) 
from bacteria and generates CO. CO is emitted by the host macrophage and 
functions to probe and “assess” the environment. If bacteria are present, 
CO compels the bacteria to generate ATP, which acts as a danger signal for 
the macrophage. The bacteria-derived ATP binds to a purinergic receptor on 
the macrophage, leading to changes in intracellular K+ concentrations. This 
signal in turn activates the inflammasome to drive pathogen clearance.
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ELISA
Mouse IL-1β and TNF-α ELISA (R&D Systems) were performed in 
cell culture supernatants, serum, or peritoneal washes following the 
manufacturer’s protocol.
RNA isolation, cDNA synthesis, and real-time PCR
RNA was isolated from cell lysates following the manufacturer’s pro-
tocol using RNeasy Mini RNA Isolation Kit (QIAGEN). cDNA was 
synthesized using 2 μg RNA and transcribed with the cDNA Synthe-
sis Kit (BioRad). Real-time PCR was performed with SYBR Green 
PCR Master Mix (BioRad) and the following primers: IL-1β, forward: 
5′-TGGGCCTCAAAGGAAAGA-3′, reverse: 5′-GGTGCTGATGTAC-
CAGTT-3′; ASC, forward: 5′-AGACATGGCTTACAGGA-3′, reverse: 
5′-CTCCTCATCTTGTCTTGG-3′; HO-1, forward: 5′-CAGGATTT-
GTCAGAGGCCCTGAAGG-3′, reverse: 5′-TGTGGTACAGGGAG-
GCCATCACC-3′; actin, forward: 5′-TAGACTTCGAGCAGGA-
GATGGC-3′, reverse: 5′-CCACAGGATTCCATACCCAAGA-3′; 
caspase-1, forward: 5′-TGAAAGAGGTGAAAGAATT-3′, reverse: 
5′-TCTCCAAGACACATTATCT-3′; NLRP3/NALP3, forward: 
5′-CTGTGTGTGGGACTGAAGCAC-3′, reverse: 5′-GCAGCCCT-
GCTGTTTCAGCAC-3′; and P2X7, forward: 5′-CGAGTTGGTGC-
CAGTGTGGA-3′, reverse: 5′-CCTGCTGTTGGTGGCCTCTT-3′. 
HO-1 primers were previously described (2).
Immunoblotting
Immunoblotting was performed as previously described (42). β-Actin 
(Sigma-Aldrich), pro–IL-1β (Milipore), caspase p20 (Cell Signaling), 
and IL-1β antibody (Millipore) were acquired as indicated. HO-1 
antibodies were from Calbiochem/Millipore or Epitomics/Abcam. 
Total Akt antibody was purchased from Cell Signaling.
Statistics
All values are expressed as the average ± SD. All experiments were 
repeated as at least 2 to 3 independent experiments in duplicate 
or triplicate. Samples were analyzed using 1-way ANOVA followed 
by Tukey’s multiple comparison test or Student’s t test (2 tailed). 
A P value of less than 0.05 was considered to be significant. When 
appropriate, Kruskal Wallis and Mann-Whitney tests were applied. 
Analyses were performed using SPPS13.0 and/or Graphpad; consul-
tation was with Shiva Gautam, biostatistician at the Harvard Univer-
sity Clinical and Translational Science Center.
Study approval
Animal protocols were approved by the Institutional Animal 
Care and Use Committees at the BIDMC, the Gulbenkian Insti-
tute, Yale University, Alfama Inc., and the University of Pitts-
burgh Medical Center.
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HO-1–derived CO, BMDMs were treated with LPS (10 ng/ml) to 
induce HO-1 and then treated with or without QC-15 (25 μM). The 
supernatants from these cells were then rapidly transferred onto 
bacteria as described above. The supernatants were incubated with 
His-tagged rbsA recombinant protein (MBS1123212; MyBioSource) 
for 30 minutes at 37°C.
BMDMs or bacterial lysates from the above were immunoprecipitat-
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was determined by phosphor imaging. Data are presented as intensity 
as a percentage of the macrophage cultures treated with the supernatant 
from 32P-treated bacteria treated in standard culture (without CO) or as 
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Potassium flux
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bation for 1 hours at 24°C with loading buffer following the manufac-
turer’s protocol. Cells were treated with CO or ATP for 30 minutes 
and scraped from the plates immediately after treatment. Basal fluo-
rescence was recorded in 96-well plates in the cell suspensions using 
FITC filters. Stimulus buffer was added, and the fluorescence corre-
sponding to the cytosolic levels of K+ was measured within 5 minutes.
Bacterial killing in vivo and in vitro
Samples for bacterial count determination were diluted from ×10 to 
1,000×, and 20 μl were plated on LB-agar plates and incubated over-
night in triplicate; the dilution that gave a minimal count of 200 colo-
nies/plate was used to determine clearance as previously described 
(37). Initial doses and kinetics are presented in the figure legends.
Bioluminescence. Bacteria counts in vivo were also measured by 
employing the bioluminescent E. coli strain Xen 14. Mice were injected 
with Xen 14, followed 1 hour later by CO (250 ppm) or air exposure for 
1 hour. Bioluminescence was measured over time in anesthetized ani-
mals (2% v/v isoflurane) at specified intervals using a Xenogen IVIS–50 
Bioluminescence Reader housed and operated by the BIDMC Small 
Animal Imaging Facility. Luciferase or D-Luciferin was injected where 
indicated (20 mg/kg, i.p.), and imaging commenced immediately.
ALT measurement
Whole-blood samples were centrifuged at 6,000 g for 5 minutes, and 
the serum was collected. Aminotransferase levels were measured 
using Automated Diagnostic Analyzer (IDEXX Laboratories).
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